Status:
RECRUITING
The Registry of Genetic Alterations of Taiwan Ovarian Cancer
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborating Sponsors:
National Taiwan University Hospital
Mackay Memorial Hospital
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Despite recent progress in chemotherapy and targeted therapy for ovarian cancer, the 5-year survival rate remains around 40% because of rapid development of treatment resistance and recurrence. The se...
Detailed Description
Development of an integrated database of genetic background from treatment-naïve or recurrent populations, clinical information, and therapeutic outcomes in primary and recurrent ovarian cancer of hig...
Eligibility Criteria
Inclusion
- Age 18 and above.
- Stage I to IV high grade serous or clear cell carcinoma of ovary, peritoneal and fallopian tube.
- Patients with primary ovarian cancer had undergone primary surgery. Patients with recurrent ovarian cancer had undergone primary surgery (and biopsy/surgery for recurrent tumors).
- Tumor tissues before neoadjuvant therapy will be collected for patients receiving surgery after any neoadjuvant treatment.
- Willingness to provide the surgical tissues of primary tumors, non-tumor part normal tissue (and paired recurrent tumors in 80 patients).
- Willingness to provide blood sample of 20ml within four weeks after registration (in at least 72 patients of primary ovarian cancer and 72 patients of recurrent ovarian cancer).
- Patient fully understand the protocol with the willingness to have regular follow-up.
- Life expectancy more than 3 months.
Exclusion
- Concomitant ovarian and endometrial cancer
- Paraffin tissue tumor block older than five years.
- Tumor specimen of primary surgery or recurrent biopsy/surgery are not qualified for genetic testing.
- Concomitant malignancy under surveillance or treatment in the past three years (excluding curatively treated basal or squamous cell skin carcinoma or carcinoma in situ)
- Inability to cooperate or undesirable compliance to the study.
Key Trial Info
Start Date :
December 13 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2031
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06127446
Start Date
December 13 2023
End Date
December 31 2031
Last Update
May 21 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang Gung Medical Foundation
Kaohsiung City, Taiwan
2
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan
3
China Medical University Hospital
Taichung, Taiwan
4
Taichung Veterans General Hospital
Taichung, Taiwan